Prevention of Atrial Fibrillation using Vaughan Williams Class IC Drugs for Multiple Premature AtrialContractions: A Clinical Observational Study
Article Sidebar
Main Article Content
Abstract
Background: Atrial fibrillation (A-Fib) poses a significant clinical challenge, particularly in the elderly and those with hypertension. If A-Fib represents one stage in the spectrum of electrical degeneration caused by aging-induced remodeling of the left atrial wall, catheter ablation is not an essential treatment. The efficacy of Vaughan Williams Class IC drug in preventing the progression of multiple premature atrial contractions (mPAC) toward paroxysmal atrial fibrillation (PAF) and A-Fib in the earlier stage of histological change was investigated.
Method and results: Group A (4 patients with mPAC) and Group B (9 patients with PAF) were treated with Class IC drugs. Treatment outcomes were compared between these two Groups and Group C (8 patients with chronic A-Fib).
Follow-up assessments were performed to evaluate the maintenance of sinus rhythm.
All mPAC patients maintained sinus rhythm during the follow-up period. In the PAF group, 8 out of 9 patients maintained their sinus rhythm.
Conclusion: Early treatment with Class IC drugs shows promise in preventing the progression of A-Fib and maintaining sinus rhythm in patients with mPAC and PAF. These findings highlight the potential role of pharmacological therapy in delaying the onset of A-Fib, thereby improving clinical outcomes and reducing the need for invasive procedures such as ablation.
Article Details
Copyright (c) 2024 Yamaguchi A.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The Journal of Cardiology and Cardiovascular Medicine is committed in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. In order to use the Open Access paradigm to the maximum extent in true terms as free of charge online access along with usage right, we grant usage rights through the use of specific Creative Commons license.
License: Copyright © 2017 - 2025 | 
Open Access by Journal of Cardiology and Cardiovascular Medicine is licensed under a Creative Commons Attribution 4.0 International License. Based on a work at Heighten Science Publications Inc.
With this license, the authors are allowed that after publishing with the journal, they can share their research by posting a free draft copy of their article to any repository or website.
Compliance 'CC BY' license helps in:
| Permission to read and download | ✓ |
| Permission to display in a repository | ✓ |
| Permission to translate | ✓ |
| Commercial uses of manuscript | ✓ |
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
Haïssaguerre M, Jaïs P, Shah DC, Takahashi A, Hocini M, Quiniou G, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339(10):659-665. Available from: https://doi.org/10.1056/nejm199809033391003
Vaughan Williams EM. Classification of antiarrhythmic drugs. In: Snadoe E, Flensted-Jensen E, Olsen KH, editors. Symposium on cardiac arrhythmias, Elsinore, Denmark. Astra; 1970; 449-472.
Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321(7):406-412. Available from: https://doi.org/10.1056/nejm198908103210629
Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian Gambit: A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation. 1991;84(5):1831-1851. Available from: https://doi.org/10.1161/01.cir.84.4.1831
Kodama I, Aizawa Y, Atarashi H. JCS 2009 guidelines for drug treatment of arrhythmias. Jpn Circ J. 2009;73(5):907-946.
January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Circulation. 2019;140(2). Available from: https://doi.org/10.1016/j.jacc.2019.01.011
Takase B, Ikeda T, Shimizu W, Abe H, Aiba T, Chinushi M, et al. JCS/JHRS 2022 guideline on diagnosis and risk assessment of arrhythmia. Jpn Circ J. 2022;86(7):935-963. Available from: https://doi.org/10.1253/circj.cj-22-0827
Kato T, Yamashita T, Sagara K, Iinuma H, Fu LT. Progressive nature of paroxysmal atrial fibrillation: observations from a 14-year follow-up study. Circ J. 2004;68(6):568-572. Available from: https://doi.org/10.1253/circj.68.568
Wazni OM, Dandamudi G, Sood N, Hoyt R, Tyler J, Durrani S, Niebauer M, et al. Cryoballoon ablation as initial therapy for atrial fibrillation. N Engl J Med. 2021;384(4):316-324. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2029554
Andrade JG, Deyell MW, Macle L, Wells GA, Bennett M, Essebag V, et al. Progression of atrial fibrillation after cryoablation or drug therapy. N Engl J Med. 2023;388(1):105-116. Available from: https://doi.org/10.1056/nejmoa2212540
Gaita F, Scaglione M, Battaglia A, Matta M, Gallo C, Galatà M, et al. Very long-term outcome following transcatheter ablation of atrial fibrillation: Are results maintained after 10 years of follow-up? Europace. 2018;20(3):443-450. Available from: https://doi.org/10.1093/europace/eux008
Morillo CA, Klein GJ, Jones DL, Guiraudon CM. Chronic rapid atrial pacing: structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation. 1995;91(6):1588-1595. Available from: https://doi.org/10.1161/01.cir.91.5.1588
Allessie M, Ausma J, Schotten U. Electrical, contractile, and structural remodeling during atrial fibrillation. Cardiovasc Res. 2002;54(1):230-246. Available from: https://doi.org/10.1016/s0008-6363(02)00258-4
Spach MS, Heidlage JF, Dolber PC, Barr RC. Changes in anisotropic conduction caused by remodeling cell size and the cellular distribution of gap junction and Na(+) channels. J Electrocardiol. 2001;34 Suppl:69-76. Available from: https://doi.org/10.1054/jelc.2001.28833
Kainuma S, Masai T, Yoshitatsu M, Miyagawa S, Yamauchi T, Takeda K, et al. Advanced left-atrial fibrosis is associated with unsuccessful maze operation for valvular atrial fibrillation. Eur J Cardiothorac Surg. 2011;40(1):61-69. Available from: https://doi.org/10.1016/j.ejcts.2010.11.008
Marrouche NF, Wilber D, Hindricks G, Jais P, Akoum N, Marchlinski F, et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: The DECAAF Study. JAMA. 2014;311(5):498-506. Available from: https://jamanetwork.com/journals/jama/fullarticle/1820433
Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: A study in awake chronically instrumented goats. Circulation. 1995;92(7):1954-1968. Available from: https://doi.org/10.1161/01.cir.92.7.1954
Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Update on hypothetical model of Alzheimer’s disease biomarkers. Lancet Neurol. 2013;12(3):207-216. Available from: https://doi.org/10.1016/s1474-4422(12)70291-0
Binici Z, Intzilakis T, Nielsen OW, Kober L, Sajadieh A. Excessive supraventricular ectopic activity and increased risk of atrial fibrillation and stroke. Circulation. 2010;121(16):1904-1911. Available from: https://doi.org/10.1161/circulationaha.109.874982
Acharya T, Tringali S, Bhullar M, Nalbandyan M, Ilineni VK, Carbajal E, et al. Frequent atrial premature complexes and their association with risk of atrial fibrillation. Am J Cardiol. 2015;116(12):1852-1857. Available from: https://doi.org/10.1016/j.amjcard.2015.09.025
Durmaz E, Ikitimur B, Kilickiran Avci B, Atıcı A, Yurtseven E, Tokdil H, et al. The clinical significance of premature atrial contractions: How frequent should they become predictive of new-onset atrial fibrillation? Ann Noninvasive Electrocardiol. 2020;25(5). Available from: https://doi.org/10.1111/anec.12718
Kirchhof P, Toennis T, Goette A, Camm AJ, Diener HC, Becher N, et al. Anticoagulation with Edoxaban in patients with atrial high-rate episodes. N Engl J Med. 2023;OA2303062. Available from: https://doi.org/10.1056/nejmoa2303062
Joglar JA, Chung MK, Armbruster AL, Benjamin E, Chyou JY, Cronin EM, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1). Available from: https://doi.org/10.1161/CIR.0000000000001193
Takaku F, et al. Analysis of fatal cases related to catheter ablation. Announcement list. Medical Accident Investigation and Support Center of Japan Medical Safety Organization. 2021.
Reddy VY, Neuzil P, Koruth JS, Petru J, Funosako M, Cochet H, et al. Pulsed field ablation for pulmonary vein isolation in atrial fibrillation. J Am Coll Cardiol. 2019;74(3):315-326. Available from: https://doi.org/10.1016/j.jacc.2019.04.021
Gunawardene MA, Schaeffer BN, Jularic M, Eickholt C, Maurer T, Akbulak RÖ, et al. Coronary spasm during pulsed field ablation of the mitral isthmus line. JACC Clin Electrophysiol. 2021;7(12):1618-1620. Available from: https://doi.org/10.1016/j.jacep.2021.08.016
Reddy VY, Gerstenfeld EP, Natale A, Whang W, Cuoco FA, Patel C, et al. Pulsed field or conventional thermal ablation for paroxysmal atrial fibrillation. N Engl J Med. 2023;389(16):1660-1671. Available from: https://doi.org/10.1056/nejmoa2307291
Kraft RO, Myers J, Overton S, Fry WJ. Vagotomy and the gastric ulcer. Am J Surg. 1971;121(2):122-128. Available from: https://doi.org/10.1016/0002-9610(71)90088-2